Effectiveness of sodium-glucose cotransporter 2 inhibitors in patients with metabolic dysfunction-associated steatotic liver disease: systematic review and meta-analysis of randomized controlled trials.
Milena Ramos Tomé, Jingying Elena Chen, Alana Vitória Santos de Jesus et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the effectiveness of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Analyzing 29 randomized controlled trials with 2443 participants, the study found that SGLT2i significantly reduced liver stiffness by 0.47 kPa and controlled attenuation parameter (CAP) by 12.24 dB/m, indicating improved liver health.
Key findings
- SGLT2i reduced liver stiffness by 0.47 kPa (95% CI: -0.88 to -0.07; P = 0.022).
- Controlled attenuation parameter (CAP) decreased by 12.24 dB/m (95% CI: -20.12 to -4.35; P = 0.002).
- FIB-4 score improved by 0.22 (95% CI: -0.38 to -0.06; P = 0.008).
- Improvements were noted in liver enzymes, body weight, and metabolic parameters.
Why it matters
The findings suggest that SGLT2 inhibitors may offer a therapeutic option for managing MASLD, a condition with limited treatment options. Improved liver health and metabolic parameters could significantly impact patient outcomes.